MetaCap

Pasithea Therapeutics (KTTA) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, gaining 63.9% versus a loss of 78.2%. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $16.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KTTA+63.94%SHPH-78.19%
+428%+160%-107%
Nov 21, 20251 yearNov 20, 2026
KTTA-97.92%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KTTA versus SHPH key metrics
MetricKTTASHPH
Share price$0.4787$3.49
Market cap$17.59M$16.63M
1-day change-0.48%-10.51%
YTD return-62.89%-80.61%
1-year return+63.94%-78.19%
5-year return-99.40%—
EPS (TTM)$-1.38$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-20.43M$-11.72M
52-week high$2.06$44.40
52-week low$0.32$2.58
Distance from 52-week high-76.76%-92.14%
Analyst consensusnone—
Avg. price target upside+526.70%—
Average volume705.64K41.80K
Shares outstanding36.75M4.76M
Employees52
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed SHPH by 142.1 percentage points over the past year.

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

KTTA vs SHPH FAQ

Which is bigger, Pasithea Therapeutics or Shuttle Pharmaceuticals?

Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).

Which stock has performed better over the past year, KTTA or SHPH?

KTTA returned +63.94% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.

Are Pasithea Therapeutics and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons